We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Nestle to Gain Peanut Allergy Drug in Aimmune Acquisition
Nestle to Gain Peanut Allergy Drug in Aimmune Acquisition
Nestlé has announced that it will acquire Aimmune Therapeutics for $2.6 billion in a deal that will add Palforzia — the first FDA-approved treatment for patients with peanut allergy — to Nestlé’s pharmaceuticals portfolio.